ANZ journal of surgery · 2024
Baseline characteristics of patients with degenerative cervical myelopathy in Australia: analysis from the MYelopathy NAtural History registry.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Najib Nashwa, Yataganbaba Alper, Briggs Nancy E, Ghahreman Ali, Mobbs Ralph, Rao Prashant J, Hansen Mitchell, Davies Mark, Kohan Saeed, Kulkarni Vinay, Sial Alisha, Ambikaipalan Anuruthran, Diwan Ashish D
Аннотация
BACKGROUND: Degenerative Cervical Myelopathy (DCM) is the most common cause of non-traumatic, chronic spinal cord dysfunction worldwide, causing debilitating disability with a diminishing quality of life. The natural history of DCM is poorly understood. This is a preliminary report of the first 60 patients recruited to the MYelopathy NAtural History (MYNAH) Registry.
METHODS: MYNAH Registry is an investigator-initiated, multicenter, prospective, non-interventional, longitudinal, national observational study (Registry ID ACSQHC-ARCR-258). Given the observational nature of the Registry, participants' clinical management plan is neither changed nor affected. Participants are recruited via an opt-in approach. A patient with DCM diagnosed by a spine/neurosurgeon after 1st January 2018 onwards is eligible to participate regardless of their surgical status. The Patient-Reported Outcome Measures (PROMs) are NDI, EQ5D5L and EQ-VAS; and the Practitioner-Reported Outcome Measures (PrROMs) are mJOA Score and Nurick Grade.
RESULTS: Sixty participants (n = 60) have now been recruited of which male participants 34 (56.7%) and females are 26 (43.3%), with a mean age of 62.3 years (SD 14.1) and biospecimens for Proteomics have been collected from 33 (66%) participants. The median mJOA Score was 16.5 (8-18), with myelopathy severity recorded as mild in 42 (70%), moderate in 13 (21.7%) and severe in 5 (8.3%) participants. Median Nurick Grade 0 (0-5), NDI 14 (0-45), EQ5D5L Score 0.850 (-0.288-1) and EQ-VAS 70 (10-96).
CONCLUSIONS: The MYNAH National DCM Registry in Australia is a novel spinal surgical initiative, that will inform the decision(s) to proceed with the scientific, evidence-based and personalised management of DCM globally in the future.
METHODS: MYNAH Registry is an investigator-initiated, multicenter, prospective, non-interventional, longitudinal, national observational study (Registry ID ACSQHC-ARCR-258). Given the observational nature of the Registry, participants' clinical management plan is neither changed nor affected. Participants are recruited via an opt-in approach. A patient with DCM diagnosed by a spine/neurosurgeon after 1st January 2018 onwards is eligible to participate regardless of their surgical status. The Patient-Reported Outcome Measures (PROMs) are NDI, EQ5D5L and EQ-VAS; and the Practitioner-Reported Outcome Measures (PrROMs) are mJOA Score and Nurick Grade.
RESULTS: Sixty participants (n = 60) have now been recruited of which male participants 34 (56.7%) and females are 26 (43.3%), with a mean age of 62.3 years (SD 14.1) and biospecimens for Proteomics have been collected from 33 (66%) participants. The median mJOA Score was 16.5 (8-18), with myelopathy severity recorded as mild in 42 (70%), moderate in 13 (21.7%) and severe in 5 (8.3%) participants. Median Nurick Grade 0 (0-5), NDI 14 (0-45), EQ5D5L Score 0.850 (-0.288-1) and EQ-VAS 70 (10-96).
CONCLUSIONS: The MYNAH National DCM Registry in Australia is a novel spinal surgical initiative, that will inform the decision(s) to proceed with the scientific, evidence-based and personalised management of DCM globally in the future.